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Background: The exact mechanism by which non-steroidal anti-inflammatory drugs (NSAIDs) increase coronary risk is not completely understood. 
We aimed to quantify the risk of each type of acute coronary syndrome (ACS) associated with the use of NSAIDs and the influence of dose, duration, 
and patient characteristics.
Methods: A prospective case-control study was performed interviewing 2,954 patients hospitalized for ACS in 32 Spanish hospitals, and a similar 
number of age-matched controls, with a structured questionnaire collecting information on the use of NSAIDs, risk factors and prior cardiovascular 
history. Odds ratios (OR were calculated overall and for each ACS type adjusted for sex, body mass index, other risk factors, and concomitant 
medications by conditional logistic regression.
Results:  The adjusted OR of ACS associated with current use of NSAIDs was 1.16 (95% confidence interval [CI], 0.95-1.42). The risk was increased 
in patients consuming high doses (OR 1.64, 95%CI, 1.06-2.53), and those with previous ischemic heart disease (OR 1.84, 90%CI 1.13-3.00). The 
hazard was mostly driven by the increase in the risk of non ST-segment elevation ACS (OR 1.20, 95% CI 0.99-1.47), while NSAIDs did not increase 
the risk of ST-segment elevation myocardial infarction (OR 1.00, 95% CI 0.80-1.26).
Conclusions:  The use of NSAIDs is associated with a small non-significant overall coronary risk, which was more apparent for non-ST-segment 
elevation ACS. This risk was stronger when used at high doses or in patients with previous ischemic heart disease.
